The therapeutic armamentarium of acute myeloid leukemia (AML) has rapidly expanded in
the past few years, driven largely by translational research into its genomic landscape and …

Retinoids (ie, vitamin A, all-trans retinoic acid, and related signaling molecules) induce the
differentiation of various types of stem cells. Nuclear retinoic acid receptors mediate most but …

Nuclear hormone receptors (NRs) are ligand-binding transcription factors that are widely
targeted therapeutically. Agonist binding triggers NR activation and subsequent degradation …

Arsenic, an ancient drug used in traditional Chinese medicine, has attracted worldwide
interest because it shows substantial anticancer activity in patients with acute promyelocytic …

Selective targeting of cancer stem cells (CSCs) offers promise for a new generation of
therapeutics. However, assays for both human CSCs and normal stem cells that are …

The concept of differentiation therapy emerged from the fact that hormones or cytokines may
promote differentiation ex vivo, thereby irreversibly changing the phenotype of cancer cells …

Haematopoietic stem cells (HSCs) in mouse bone marrow are located in specialized niches
as single cells. During homeostasis, signals from this environment keep some HSCs …

Histone deacetylases (HDACs) are a key component of the epigenetic machinery regulating
gene expression, and behave as oncogenes in several cancer types, spurring the …

Historically, acute promyelocytic leukemia (APL) was considered to be one of the most fatal
forms of acute leukemia with poor outcomes before the introduction of the vitamin A …

Recent clinical trials have demonstrated that the immense majority of acute promyelocytic
leukemia (APL) patients can be definitively cured by the combination of two targeted …